# Maravai Lifesciences Holdings (MRVI.US)

Canonical: https://gigainvestors.com/s/MRVI

Analysis as of: 2026-10-16T07:30:22.923Z. Financial observations: FY2018–FY2026.

Listing currency: USD. Reporting currency: USD.

## Verdict

Not a wonderful business

Quality tests for Buy: not passed (profit record: fail; earnings resilience is evidence only). Published buy qualification: no.

Share price: $7.07 per share; close as of 2026-10-15.

## Checklist

### understandable: fail

- 3 revenue declines in the last 10 years (informational)

- more than 2 net loss years

- operating margin variation exceeds 0.35

- Financial history: 9 years

- Years with declining revenue: 3

- Years with a net loss: 6

- Operating margin variation: 2.84×

Chart: Operating margin; fiscal year observations.

- FY2018: 0.13×

- FY2019: 0.17×

- FY2020: 0.42×

- FY2021: 0.69×

- FY2022: 0.65×

- FY2023: -0.11×

- FY2024: -0.91×

- FY2025: -0.04×

- LTM to Jun 2026: 0.46×

### moat: fail

- Years with nonpositive invested capital use equity plus debt and leases; positive earnings with no positive capital are shown above 100%.

- ROIC median below threshold

- ROIC worst years below threshold (more than 1 bad year allowed)

- Recent gross margin fell 16.3pp below the typical margin (limit 4pp)

- ROIC, median of available years: 6.7%

- ROIC, second-lowest year: -16.2%

- Typical minus recent gross margin: 16.3 pp

- Typical gross margin (annual median): 50.9%

- Recent gross margin (lower of latest and 3-year median): 34.6%

- Years with nonpositive capital: 1

- Capital spending / revenue: 7.1%

- ROIC including acquisitions, ten-year median: -0.0%

Chart: ROIC excluding acquisitions; fiscal year observations.

- FY2018: 5.5%

- FY2019: 6.7%

- FY2020: 52.9%

- FY2021: >100%

- FY2022: >100%

- FY2023: -16.2%

- FY2024: -84.7%

- FY2025: -2.1%

- LTM to Jun 2026: 41.8%

### economics: fail

- incremental invested capital return below threshold

- Owner earnings / net income, 5-yr: 10.35×

- Cash conversion uses consolidated totals: No

- Owner earnings, five-year total: $79M

- Net income, five-year total: $7.6M

- Return on incremental invested capital: 0.0%

- Working capital / revenue, annual change: 1.9 pp

Chart: Annual owner cash / profit; fiscal year observations.

- FY2021: 1.02×

- FY2022: 1.04×

- FY2023: 1.14×

- FY2024: 0.81×

- FY2025: 0.64×

### management: fail

- potential debt-funded buybacks (informational)

- buybacks leaned toward cheaper years (informational)

- ROIC first 3 years vs last 3 years: 6.7% vs -16.2%

- Per-share earnings: -0.07 to -0.91 (three-year endpoint medians)

- per-share value declined or ends nonpositive

- Management verdict uses per-share economic progress: Yes

- Ordinary dilution, 5-year annual growth: 4.8%

- Diluted shares, 5-year annual growth: 4.8%

- Per-share value change: -$0.84

- Per-share value, starting three-year median: -$0.07

- Per-share value, ending three-year median: -$0.91

- Buybacks concentrated in cheaper years (correlation): 0.50

- Average buyback yield: 15.2%

- Buyback history: 3 years

- Debt-funded buybacks: Yes

- ROIC, first three-year median: 6.7%

- ROIC, last three-year median: -16.2%

Chart: Earnings per share; fiscal year observations.

- FY2018: -$0.07

- FY2019: -$0.09

- FY2020: $0.67

- FY2021: $1.49

- FY2022: $0.86

- FY2023: -$0.90

- FY2024: -$1.05

- FY2025: -$0.91

### accounting: pass

- restructuring or one-time charges in at least three of five years

- Sloan accruals: -9.5%

- Receivables to sales index (DSRI): 0.92×

- Restructuring years, last five: 3

- Earnings backed by cash: Yes

- Accounting red flags: 1

- Goodwill and intangibles / equity: 1.32×

Chart: Sloan accruals; fiscal year observations.

- FY2018: -3.3%

- FY2019: -5.6%

- FY2020: -5.9%

- FY2021: -9.7%

- FY2022: -13.8%

- FY2023: -16.5%

- FY2024: -15.1%

- FY2025: -9.5%

## Holders

- [Matthew McLennan](https://gigainvestors.com/FE): tracked 13F investor; follow the investor page for holding quarter and amounts.

- [Steven Romick](https://gigainvestors.com/FPA): tracked 13F investor; follow the investor page for holding quarter and amounts.

## Price story

Down 85% since Nov 2021 · "Maravai signals $50M annualized cost reduction plan as leadership targets positive EBITDA in 2026" (seekingalpha.com, Aug 2025) · sales +12.4%

Story as of 2026-10-16T09:59:12.206Z; price observation 2026-10-15.

- 2025-08-12: Maravai signals $50M annualized cost reduction plan as leadership targets positive EBITDA in 2026 ([seekingalpha.com](https://seekingalpha.com/news/4483625-maravai-signals-50m-annualized-cost-reduction-plan-as-leadership-targets-positive-ebitda-in?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news))

- 2026-08-07: Maravai outlines $33M-$35M 2026 adjusted EBITDA outlook while maintaining $205M-$215M revenue range ([seekingalpha.com](https://seekingalpha.com/news/4628981-maravai-outlines-33m-35m-2026-adjusted-ebitda-outlook-while-maintaining-205m-215m-revenue?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news))

### Sales · FY2025–2026

sales +12.4%; source https://www.sec.gov/Archives/edgar/data/1823239/000182323926000011/mrvi-20251231.htm; observed 2026-02-26.

- FY2018: $124M 

- FY2019: $143M 

- FY2020: $284M 

- FY2021: $799M 

- FY2022: $883M 

- FY2023: $289M 

- FY2024: $259M 

- FY2025: $186M 

- FY2026: $209M 

### Gross margin · FY2026

gross margin 34.6%; source https://www.sec.gov/Archives/edgar/data/1823239/000182323926000011/mrvi-20251231.htm; observed 2026-02-26.

- FY2018: 50.9% 

- FY2019: 53.3% 

- FY2020: 72.0% 

- FY2021: 82.4% 

- FY2022: 80.9% 

- FY2023: 48.5% 

- FY2024: 41.8% 

- FY2025: 18.0% 

- FY2026: 34.6% 

## Owner memo

Memo as of 2026-10-16T08:06:05.509Z.

### How it makes money

Operates in biotechnology; annual sales are USD 185.7 million.

- Source: https://www.sec.gov/Archives/edgar/data/1823239/000182323926000011/mrvi-20251231.htm (filed 2026-02-26); FY2025: revenue 185743000; grossProfit 33390000; margin = grossProfit / revenue.

### Why customers stay

Margins ranged from 18% to 48.5% during 2023–25; it earns 6.7% on its capital.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-02-26); FY2023: grossProfit / revenue = 48.5%.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-02-26); FY2024: grossProfit / revenue = 41.8%.

- Source: https://www.sec.gov/Archives/edgar/data/1823239/000182323926000011/mrvi-20251231.htm (filed 2026-02-26); FY2025: grossProfit / revenue = 18%.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-02-26); 9-year return on capital observations [[2018,0.054521421103240354],[2019,0.06705229227628325],[2020,0.528600062537695],[2021,2.6267534703876603],[2022,2.3798834235887556],[2023,-0.16232432986924855],[2024,-0.847207553696514],[2025,-0.021467252782706888],[2026,0.4175443624242291]]; median 0.06705229227628325. ROIC follows the displayed moat series; financial companies use return on tangible equity.

### Where the cash goes

Paid dividends in 4 of 8 years.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-02-26); FY2018: growth capex 0; upkeep 3611000; owner earnings 1005000. Growth capex / owner earnings = 0.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-02-26); FY2020: growth capex 0; upkeep 25408000; owner earnings 77317000. Growth capex / owner earnings = 0.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-02-26); FY2021: growth capex 0; upkeep 14850000; cash acquisitions 0; owner earnings 185878300.74374002. Growth capex plus acquisitions / owner earnings = 0.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-02-26); FY2022: growth capex 0; upkeep 17090000; cash acquisitions 238969000; owner earnings 229635439.35450605. Growth capex plus acquisitions / owner earnings = 1.0406451228596516.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-02-26); Dividend observations: [[2018,52056000],[2019,97051000],[2020,609321000],[2021,153451000],[2022,0],[2023,0],[2024,0],[2025,0]]. Zero only counted when supported by a complete cash-flow statement.

### What the price says

The price is 5.5 times annual sales; cash earnings are negative.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-02-26); Closing price 7.07 USD; reporting-to-trading FX 1; FY2025 annual sales per share 1.286665281241341; price multiple 5.494824569431957. FY2025 cash earnings/share -0.5780687170961485. Closing-price date 2026-10-15.

## Monthly share-price history (USD per share)

- 2020-11: $28.15 per share

- 2020-12: $28.05 per share

- 2021-01: $34.84 per share

- 2021-02: $32.52 per share

- 2021-03: $35.64 per share

- 2021-04: $38.91 per share

- 2021-05: $37.54 per share

- 2021-06: $41.73 per share

- 2021-07: $43.97 per share

- 2021-08: $59.18 per share

- 2021-09: $49.08 per share

- 2021-10: $42.29 per share

- 2021-11: $45.94 per share

- 2021-12: $41.90 per share

- 2022-01: $28.92 per share

- 2022-02: $39.07 per share

- 2022-03: $35.27 per share

- 2022-04: $30.73 per share

- 2022-05: $31.15 per share

- 2022-06: $28.41 per share

- 2022-07: $26.09 per share

- 2022-08: $20.87 per share

- 2022-09: $25.53 per share

- 2022-10: $16.60 per share

- 2022-11: $14.88 per share

- 2022-12: $14.31 per share

- 2023-01: $14.66 per share

- 2023-02: $14.75 per share

- 2023-03: $14.01 per share

- 2023-04: $13.79 per share

- 2023-05: $12.84 per share

- 2023-06: $12.43 per share

- 2023-07: $11.31 per share

- 2023-08: $10.34 per share

- 2023-09: $10.00 per share

- 2023-10: $6.86 per share

- 2023-11: $5.10 per share

- 2023-12: $6.55 per share

- 2024-01: $5.80 per share

- 2024-02: $7.73 per share

- 2024-03: $8.67 per share

- 2024-04: $8.20 per share

- 2024-05: $8.67 per share

- 2024-06: $7.16 per share

- 2024-07: $9.73 per share

- 2024-08: $9.05 per share

- 2024-09: $8.31 per share

- 2024-10: $7.41 per share

- 2024-11: $5.67 per share

- 2024-12: $5.45 per share

- 2025-01: $4.93 per share

- 2025-02: $3.22 per share

- 2025-03: $2.21 per share

- 2025-04: $2.02 per share

- 2025-05: $2.25 per share

- 2025-06: $2.41 per share

- 2025-07: $2.34 per share

- 2025-08: $2.42 per share

- 2025-09: $2.87 per share

- 2025-10: $3.14 per share

- 2025-11: $3.62 per share

- 2025-12: $3.25 per share

- 2026-01: $3.36 per share

- 2026-02: $3.56 per share

- 2026-03: $2.83 per share

- 2026-04: $3.68 per share

- 2026-05: $4.80 per share

- 2026-06: $6.24 per share

- 2026-07: $6.57 per share

- 2026-08: $7.64 per share

- 2026-09: $7.66 per share

- 2026-10: $7.07 per share

## Annual estimated value (USD per share)

- FY2022: low $9.87 per share, central $11.08 per share, high $12.70 per share

- FY2023: low $7.84 per share, central $8.61 per share, high $9.63 per share

- FY2024: low $6.07 per share, central $6.73 per share, high $7.61 per share

Historical values use today's bond yield for every fiscal year

Historical values use today's FX rate into trading currency for every fiscal year

Historical values use current restated fundamentals and current commodity classification; they are not point-in-time estimates

## Sources

[Original 10-K filing](https://www.sec.gov/Archives/edgar/data/1823239/000182323926000011/mrvi-20251231.htm); period 2025-12-31, filed 2026-02-26.

Estimates depend on assumptions and are not guarantees or investment advice. Underlying data remains subject to its source licenses; public reading does not grant bulk redistribution rights.

## Reported holder observations

- [Matthew McLennan](https://gigainvestors.com/FE): 3,671,287 MRVI shares; USD 22,909,000 reported position value; 0.04% of portfolio; add; quarter 2026 Q2.
- [Steven Romick](https://gigainvestors.com/FPA): 884,883 MRVI shares; USD 5,522,000 reported position value; 0.07% of portfolio; hold; quarter 2026 Q2.

# MRVI — Maravai LifeSciences Holdings Inc.

Held by 2 investors · USD 28,431,000 total · 2026 Q2 · reported price USD 6.24 (split-adjusted).
Page: https://gigainvestors.com/s/MRVI

## Holders (2026 Q2)

| Investor | Value | % of their portfolio | This quarter |
|---|---:|---:|---|
| Matthew McLennan (https://gigainvestors.com/FE) | USD 22,909,000 | <0.1% | add +45.44% |
| Steven Romick (https://gigainvestors.com/FPA) | USD 5,522,000 | 0.1% | hold |

## Total held by quarter

- 2025 Q2: USD 1,786,610 · 1 holder · USD 2.41
- 2025 Q3: USD 3,833,786 · 2 holders · USD 2.87
- 2025 Q4: USD 8,723,712 · 2 holders · USD 3.25
- 2026 Q1: USD 9,648,090 · 2 holders · USD 2.83
- 2026 Q2: USD 28,431,000 · 2 holders · USD 6.24